Demographic and clinical characteristics of patients who initiated ART between January 2008 and December 2013 at the Themba Lethu Clinic in Johannesburg South Africa, stratified by documentation of South African citizenship
| Characteristic | Total | Confirmed South African citizen | Unconfirmed South African citizen | Foreign national |
|---|---|---|---|---|
| Total | 12 219 | 8534 | 2292 | 1393 |
| Year of ART initiation | ||||
| 2008–2009 | 4133 (33.8%) | 2927 (34.3%) | 985 (43.0%) | 221 (15.9%) |
| 2010–2011 | 4791 (39.2%) | 3324 (39.0%) | 848 (37.0%) | 619 (44.4%) |
| 2012–2013 | 3295 (27.0%) | 2283 (26.8%) | 459 (20.0%) | 553 (39.7%) |
| Sex | ||||
| Male | 4943 (40.5%) | 3346 (39.2%) | 1001 (43.7%) | 596 (42.8%) |
| Female | 7276 (59.5%) | 5188 (60.8%) | 1291 (56.3%) | 797 (57.2%) |
| Age at ART initiation | ||||
| Median (IQR) | 37.6 (31.7–44.4) | 38.4 (32.4–45.4) | 36.5 (30.8–44.0) | 34.3 (30.1–39.4) |
| <30 | 2227 (18.2%) | 1390 (16.3%) | 499 (21.8%) | 338 (24.3%) |
| 30–34.9 | 2511 (20.6%) | 1605 (18.8%) | 498 (21.7%) | 408 (29.3%) |
| 35–39.9 | 2610 (21.4%) | 1826 (21.4%) | 457 (19.9%) | 327 (23.5%) |
| 40–44.9 | 1993 (16.3%) | 1482 (17.4%) | 336 (14.7%) | 175 (12.6%) |
| ≥45 | 2878 (23.6%) | 2231 (26.1%) | 502 (21.9%) | 145 (10.4%) |
| Employment status | ||||
| Missing | 370 (3.0%) | 222 (2.6%) | 97 (4.2%) | 51 (3.7%) |
| Employed | 6691 (54.8%) | 4822 (56.5%) | 1053 (45.9%) | 816 (58.6%) |
| Unemployed | 5158 (42.2%) | 3490 (40.9%) | 1142 (49.8%) | 526 (37.8%) |
| Baseline CD4 count (cells/mm3) | ||||
| Median (IQR) | 120 (46–195) | 122 (48–197) | 101 (35–178) | 137 (58.5–210) |
| Missing | 789 (6.5%) | 484 (5.7%) | 188 (8.2%) | 117 (8.4%) |
| <50 | 2991 (24.5%) | 2047 (24.0%) | 664 (29.0%) | 280 (20.1%) |
| 50–99 | 1947 (15.9%) | 1366 (16.0%) | 373 (16.3%) | 208 (14.9%) |
| 100–199 | 3791 (31.0%) | 2683 (31.4%) | 680 (29.7%) | 428 (30.7%) |
| ≥200 | 2701 (22.1%) | 1954 (22.9%) | 387 (16.9%) | 360 (25.8%) |
| BMI at ART initiation (kg/m2) | ||||
| Median (IQR) | 21.8 (19.3–25.3) | 22.0 (19.3–25.7) | 20.8 (18.6–23.8) | 21.9 (19.7–24.9) |
| Missing | 1839 (15.1%) | 1088 (12.8%) | 497 (21.7%) | 254 (18.2%) |
| <18.5 | 1918 (15.7%) | 1328 (15.6%) | 432 (18.9%) | 158 (11.3%) |
| 18.5–24.9 | 5707 (46.7%) | 3990 (46.8%) | 1006 (43.9%) | 711 (51.0%) |
| 25–29.9 | 1812 (14.8%) | 1364 (16.0%) | 240 (10.5%) | 208 (14.9%) |
| ≥30 | 943 (7.7%) | 764 (9.0%) | 117 (5.1%) | 62 (4.5%) |
| WHO stage | ||||
| I/II | 7037 (57.6%) | 4993 (58.5%) | 1105 (48.2%) | 939 (67.4%) |
| III/IV | 5182 (42.4%) | 3541 (41.5%) | 1187 (51.8%) | 454 (32.6%) |
| Haemoglobin (g/dL) at ART initiation | ||||
| Median (IQR) | 11.1 (9.5–12.6) | 11.2 (9.6–12.6) | 10.5 (8.9–12.2) | 11.3 (9.8–12.8) |
| Anaemia at ART initiation | ||||
| Missing | 1027 (8.4%) | 623 (7.3%) | 262 (11.4%) | 142 (10.2%) |
| No anaemia | 3025 (24.8%) | 2223 (26.1%) | 420 (18.3%) | 382 (27.4%) |
| Mild anaemia | 2658 (21.8%) | 1892 (22.2%) | 457 (19.9%) | 309 (22.2%) |
| Moderate anaemia | 4455 (36.5%) | 3113 (36.5%) | 875 (38.2%) | 467 (33.5%) |
| Severe anaemia | 1054 (8.6%) | 683 (8.0%) | 278 (12.1%) | 93 (6.7%) |
| Co-infected with tuberculosis at ART initiation | ||||
| Yes | 1464 (12.0%) | 1034 (12.1%) | 338 (14.8%) | 92 (6.6%) |
| First ART regimen* | ||||
| TDF-3TC-EFV | 5576 (45.6%) | 3839 (45.0%) | 914 (39.9%) | 823 (59.1%) |
| d4T-3TC-EFV | 4918 (40.3%) | 3481 (40.8%) | 1111 (48.5%) | 326 (23.4%) |
| AZT-3TC-EFV | 286 (2.3%) | 202 (2.4%) | 61 (2.7%) | 23 (1.7%) |
| Other | 1439 (11.8%) | 1012 (11.9%) | 206 (9.0%) | 221 (15.9%) |
*3TC: lamivudine; AZT: zidovudine; d4T: stavudine; EFV: efavirenz; TDF: tenofovir; Other regimens are: TDF-3TC-NVP (nevirapine), AZT-3TC-NVP, TDF-EMT (emtricitabine)-EFV, TDF-EMT-NVP, and d4T-3TC-NVP.
ART, antiretroviral therapy; BMI, body mass index.